FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1419-1421 November 8, 2001 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The first of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (collectively referred to as "statins") was identified in 1976.¹ This enzyme was an ideal target for treating hypercholesterolemia, since it catalyzes the conversion of HMG-CoA to mevalonate, a limiting step in cholesterol synthesis. Today, statins are the most powerful hypolipidemic drugs available and are widely prescribed throughout the world.

Because lipid intermediates of cholesterol synthesis (isoprenoids) allow the attachment to the cell membrane of signaling proteins involved in various functions, statins have other biologic effects.² They can stimulate bone formation, alter the function of endothelial cells, induce apoptosis of smooth-muscle . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Belay, B., Belamarich, P. F., Tom-Revzon, C. (2007). The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. Pediatrics 119: 370-380 [Abstract] [Full Text]  
• Keating, S. M., Clark, K. R., Stefanich, L. D., Arellano, F., Edwards, C. P., Bodary, S. C., Spencer, S. A., Gadek, T. R., Marsters, J. C. Jr., Beresini, M. H. (2006). Competition between intercellular adhesion molecule-1 and a small-molecule antagonist for a common binding site on the {alpha}l subunit of lymphocyte function-associated antigen-1. Protein Sci. 15: 290-303 [Abstract] [Full Text]  
• Fuster, V., Moreno, P. R., Fayad, Z. A., Corti, R., Badimon, J. J. (2005). Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts. J Am Coll Cardiol 46: 937-954 [Abstract] [Full Text]  
• Campese, V. M., Nadim, M. K., Epstein, M. (2005). Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective?. J. Am. Soc. Nephrol. 16: S11-S17 [Abstract] [Full Text]  
• Weitz-Schmidt, G., Welzenbach, K., Dawson, J., Kallen, J. (2004). Improved Lymphocyte Function-associated Antigen-1 (LFA-1) Inhibition by Statin Derivatives: MOLECULAR BASIS DETERMINED BY X-RAY ANALYSIS AND MONITORING OF LFA-1 CONFORMATIONAL CHANGES IN VITRO AND EX VIVO. J. Biol. Chem. 279: 46764-46771 [Abstract] [Full Text]  
• Schmidmaier, R., Baumann, P., Simsek, M., Dayyani, F., Emmerich, B., Meinhardt, G. (2004). The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 104: 1825-1832 [Abstract] [Full Text]  
• Almog, Y., Shefer, A., Novack, V., Maimon, N., Barski, L., Eizinger, M., Friger, M., Zeller, L., Danon, A. (2004). Prior Statin Therapy Is Associated With a Decreased Rate of Severe Sepsis. Circulation 110: 880-885 [Abstract] [Full Text]  
• Price, C J S, Warburton, E A, Menon, D K (2003). Human cellular inflammation in the pathology of acute cerebral ischaemia. J. Neurol. Neurosurg. Psychiatry 74: 1476-1484 [Abstract] [Full Text]  
• Almog, Y. (2003). Statins, Inflammation, and Sepsis: Hypothesis. Chest 124: 740-743 [Abstract] [Full Text]  
• Kitas, G. D., Erb, N. (2003). Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42: 607-613 [Full Text]  
• Blake, G. J., Ridker, P. M. (2003). C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 41: 37S-42S [Abstract] [Full Text]  
• Kluft, C., Kleemann, R., de Maat, M.P.M. (2002). How best to counteract the enemies? By controlling inflammation in the coronary circulation. Eur Heart J Suppl 4: G53-G65 [Abstract]  
• Holstein, S. A., Wohlford-Lenane, C. L., Hohl, R. J. (2002). Consequences of Mevalonate Depletion. DIFFERENTIAL TRANSCRIPTIONAL, TRANSLATIONAL, AND POST-TRANSLATIONAL UP-REGULATION OF Ras, Rap1a, RhoA, AND RhoB. J. Biol. Chem. 277: 10678-10682 [Abstract] [Full Text]